Difference between revisions of "Riechelmann H, et al. Oral. Oncol. (2008) cited as Ref 555 in DOI: 10.1038/s41392-020-0110-5 (Q9818)"
Jump to navigation
Jump to search
(Created claim: DOI Identifier (P138): 10.1016/j.oraloncology.2007.10.009, #quickstatements; #temporary_batch_1590000649558) |
(Created claim: Page(s) (P105): 823-829, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
| (5 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / PubMed ID | |||||||||||||||
| + | |||||||||||||||
| Property / PubMed ID: 18203652 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2008
| ||||||||||||||
| Property / Publication Date: 2008 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Oral. Oncol. | ||||||||||||||
| Property / Published In Name String: Oral. Oncol. / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 44 | ||||||||||||||
| Property / Volume: 44 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma (English) | ||||||||||||||
| Property / title: Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 823-829 | ||||||||||||||
| Property / Page(s): 823-829 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
Latest revision as of 15:45, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Riechelmann H, et al. Oral. Oncol. (2008) cited as Ref 555 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Riechelmann H
0 references
2008
0 references
Oral. Oncol.
0 references
44
0 references
Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma (English)
0 references
823-829
0 references
